PacificHealth Laboratories Inc.

DR. ROBERT PORTMAN , age 64, currently serves as our non-executive Chairman of the Board of Directors. Since August 1, 2008, Dr. Portman has been Managing Principal of Signal Nutrition, a research and development company. He served as our Chief Executive Officer and Chief Scientific Officer from June 2005 through July 2008 and Chairman of the Board of Directors and Chief Scientific Officer since September 2004. He served as President from June 2005 through the end of calendar year 2007. From our inception to September 2004, Dr. Portman served as our President, Chief Executive Officer, and Chairman of the Board of Directors. Dr. Portman has a Ph.D. in Biochemistry and worked as a senior scientist at Schering Laboratories before co-founding M.E.D. Communications in 1974. In 1987, Dr. Portman started a consumer agency and, in 1993, he merged both agencies to form C&M Advertising with billings in excess of $100 million. Dr. Portman is coauthor of two books, Nutrient Timing and The Performance Zone. He has authored hundreds of articles on the role of nutrition in improving sports performance. He is a frequent guest on TV and radio and has been a keynote speaker at national coaches meetings on how nutritional intervention during and after exercise can improve athletic performance and speed muscle recovery. As the former Chief Scientific Officer of PacificHealth Laboratories, he obtained 12 patents for nutritional inventions to improve sports performance as well as to control appetite and help in the management of Type II diabetes.

STEPHEN P. KUCHEN , age 48, has served as Vice President of Finance, Chief Financial Officer, Treasurer and Secretary since June 2000. Mr. Kuchen also served as a Director from June 2000 until May 2008 and Chief Operating Officer from September 2004 until January 1, 2008. Mr. Kuchen initially joined us in February of 2000 as Controller. Prior to joining us, Mr. Kuchen was employed from 1996 to 1999 as the Controller of Able Laboratories, a public company located in South Plainfield, New Jersey that manufactured and sold generic pharmaceuticals. Prior to his employment by Able Laboratories, Mr. Kuchen was the Controller of Jerhel Plastics, a privately owned manufacturer of women's compact cases from 1993 to 1996. Mr. Kuchen is a graduate of Seton Hall University in South Orange, NJ, and is a Certified Management Accountant.

Michael E. Cahr was elected as a director on January 28, 2009, and is a member of the Audit Committee and Compensation Committee. Mr. Cahr is a general partner at Focus Equity Partners, a private equity investment and management firm that acquires middle-market companies and assists them in reaching their performance potential. Mr. Cahr has more than 30 years of experience as a venture capitalist, CEO and director of public and private companies. From September 2004 to June 2006, Mr. Cahr served as CEO of one of Focus Equity s investments, C&M Pharmacy, a Glenview, Illinois, specialty pharmacy company and engineered the sale of the company to Walgreen Co. Currently, Mr. Cahr acts as board member and advisor to another Focus investment, Business Only Broadband (BOB), a premier provider of carrier-class, fixed wireless primary and co-primary data network solutions for the business sectors in Chicago and the New York metropolitan area. Mr. Cahr serves as a director of Pacific Health Laboratories, a publicly-traded nutritional products firm that develops and commercializes functionally unique nutritional products.

Adam Mizel was appointed to the Board of Directors in March 2009. Since September 2005, Mr. Mizel has been the Managing Principal of the General Partner of the Aquifer Opportunity Fund, L.P., an investment fund that takes a private equity approach to investing in small capitalization public companies. He currently serves on the Board of Directors of PacificHealth Laboratories, Inc. (PHLI). Mr. Mizel previously was Managing Director and Chief Operating Officer of Azimuth Trust, LLC., an alternative asset management firm from 2001 until 2005. Earlier, Mr. Mizel was a partner at Capital Z Partners, L.P., a private equity and alternative investment firm, and Managing Director at Zurich Centre Investments, Inc., the North American private equity unit of Zurich Financial Services Group. Mr. Mizel began his investment career at Morgan Stanley Capital Partners in 1991.

David I. Portman rejoined our Board of Directors on February 24, 2006, and had previously served on our Board from 1993 until December 31, 2002. Mr. Portman is the president of TRIAD Development, a real estate company that has numerous commercial and rental properties in New Jersey, a position that he has held since 1988. In addition, Mr. Portman currently serves as a director of Pacifichealth Laboratories, Inc., a publicly held nutrition technology company, a position he has held since August 1995. Montauk Financial Group underwrote the initial public offering of the common stock of Pacifichealth Laboratories. Mr. Portman has a BS in Pharmacy and an MBA. He worked as a sales representative and marketing manager for Eli Lilly, Beecham-Massengill, Winthrop Laboratories and Sandoz Pharmaceuticals before co-founding M.E.D. Communications in 1974. In 1988, Mr. Portman sold his interest in M.E.D. Communications and became President of TRIAD Development.

Greg Horn is a longtime leader in the nutritional supplements industry, and has dedicated his career to building brands that enhance healthy living. Prior to joining Garden of Life, Greg was the founder and CEO of Specialty Nutrition Group, Inc. (SNG), a leading innovator in nutrition brand building from concept through launch. He was also a co-founder of Brand New Brands, Inc. a leading functional food and beverage company. In addition, he also served as Chief Executive Officer of General Nutrition Centers (GNC), and was instrumental in building the GNC brand and increasing revenues by $100 million per year from 1991 to 2002, which grew the company from $400 million to $1.5 billion in revenues and growing the retail chain from 950 to 5,600 stores. Greg holds an MBA from UCLA and a BA (summa cum laude, Phi Beta Kappa) from the University of Redlands.

Joseph is currently a venture partner and a fund manager of Trillium Lakefront Partners III, an expansion stage technology venture capital fund. Joseph formerly served as senior vice president and director of Corporate Strategy and Development for SmithKline Beecham, currently Glaxo SmithKline, a multi-billion dollar global research-based pharmaceutical company. In that role, he analyzed, planned and executed strategic transactions for the company, including acquisitions, divestitures and joint ventures. During his tenure there, he completed several transactions totaling in excess of $2 billion, including the sale of SB Clinical Laboratories to Quest Diagnostics, Inc. and the sale of Diversified Pharmaceutical Systems to Express Scripts, Inc. Prior to his position with SmithKline Beecham, Joseph served as managing director of business development for Eastman Kodak Company, a global manufacturer and marketer of traditional and digital imaging products and services. In this position, he planned and managed more than 45 strategic transactions, including acquisitions, divestitures, joint ventures and licensing transactions, totaling in excess of $10 billion. These transactions included the sale of Kodak's Clinical Diagnostics Division to Johnson & Johnson, a joint venture with Matsushita Electric, Inc. and the sale of Verbatim Corporation to Mitsubishi Kasai. Joseph has also served in senior management positions with companies manufacturing and marketing electronics and medical devices.